An observational study in Chronic Myeloid Leukemia (CML), sponsored by University Hospital, Clermont-Ferrand. Recruiting at 14 sites in France. Per ClinicalTrials.gov, last updated 2024-04-09.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their response to treatment, evaluation of new molecules in real life, therapeutic discontinuations, impact of the evolution of recommendations, etc.
Observational study collecting real-life clinico-biological data from patients with CML. Data are collected prospectively and retrospectively, from diagnosis and throughout the long-term follow-up of CML (follow up continues after treatment stopped).
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's planned enrollment of 3,500 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any patient with a diagnose of CML
Exclusion Criteria:
Clinical and biological data collection
Aims of the registry are the collection of clinical data to gain further insights about patients's CML treated with ITK's (treatment, prognosis, therapeutical response).
Time frame: Until death or last follow up (up to 30 years)
Prognosis score for CML (Sokal, ELTS, Eutos, Hasford)
Time frame: At diagnosis
BMI with evaluation of weight and height
Time frame: Until death or last follow up (up to 30 years)
Evaluation of major molecular response (MMR) with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of molecular response MR4 with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of molecular response MR4.5 with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of molecular response MR5 with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of cytogenetic response
Time frame: Until death or last follow up (up to 30 years)
Evaluation of TKI efficacy based on transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of TKI tolerance (adverses events)
Time frame: Until death or last follow up (up to 30 years)
Calcul in month of the duration of maintenance TFR (treatment free remission) after stop TKI for thérapeutic response
Time frame: Until death or last follow up (up to 30 years)
Listing of major medical history of patient's CML
Time frame: Until death or last follow up (up to 30 years)
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand